Recent study reveals nirmatrelvir treatment during acute COVID-19 does not lower the risk of post-acute COVID-19 symptoms, nor is it associated with symptomatic rebound.
Paxlovid does not help prevent long COVID-19, according to a UCSF study published this week which also showed that people are also more likely to experience a rebound infection than previously thought.